Cargando…

Editorial: Inhibiting PARP as a Strategic Target in Cancer

Detalles Bibliográficos
Autores principales:	Zorn, Kristin K., Annunziata, Christina M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831976/ https://www.ncbi.nlm.nih.gov/pubmed/27148483 http://dx.doi.org/10.3389/fonc.2016.00091

Ejemplares similares

Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity
por: Horton, Julie K., et al.
Publicado: (2013)

Editorial: Strategic molecular biomarkers and microRNAs in cancer
por: López-Camarillo, César, et al.
Publicado: (2022)

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets
por: Shah, Girish M., et al.
Publicado: (2013)

Structural Implications for Selective Targeting of PARPs
por: Steffen, Jamin D., et al.
Publicado: (2013)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
por: Ricks, Tiffany K., et al.
Publicado: (2015)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Chloroquine Triggers Cell Death and Inhibits PARPs in Cell Models of Aggressive Hepatoblastoma
por: Eloranta, Katja, et al.
Publicado: (2020)

Beyond DNA Repair: Additional Functions of PARP-1 in Cancer
por: Weaver, Alice N., et al.
Publicado: (2013)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer
por: Martincuks, Antons, et al.
Publicado: (2021)

Editorial: Molecules of the extracellular matrix as cancer targets
por: Karamanos, Nikos K., et al.
Publicado: (2022)

The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer
por: Bian, Xing, et al.
Publicado: (2020)

Editorial: Targeting MYCN in Pediatric Cancers
por: Sala, Arturo
Publicado: (2015)

Editorial: Nanomedicine in Cancer Targeting and Therapy
por: Longo, João Paulo Figueiró, et al.
Publicado: (2021)

Editorial: Engineered Targeted Cancer Immunotherapies
por: Fantini, Massimo, et al.
Publicado: (2022)

Editorial: Targeting Estrogens in Cancer Care
por: Di Donato, Marzia
Publicado: (2022)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Effectiveness of PARP inhibition in enhancing the radiosensitivity of 3D spheroids of head and neck squamous cell carcinoma
por: Zhou, Chumin, et al.
Publicado: (2022)

Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer
por: Bian, Xing, et al.
Publicado: (2023)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
por: Reinbolt, Raquel E., et al.
Publicado: (2013)

Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization
por: Conceição, Carlota J. F., et al.
Publicado: (2023)

Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells
por: Caminear, Michael W., et al.
Publicado: (2022)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

Editorial: Targeting Pancreatic Cancer: Strategies and Hopes
por: Manu, Kanjoormana Aryan, et al.
Publicado: (2022)

Editorial: Immunometabolism and therapeutic targeting of aggressive cancers
por: Ždralević, Maša, et al.
Publicado: (2023)

Editorial: Multi-target directed ligands for the treatment of cancer
por: Brindisi, Margherita, et al.
Publicado: (2022)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Editorial: Ubiquitin-Modifying Enzymes as Drug Targets and Biomarkers in Cancer
por: Bell, Jessica L., et al.
Publicado: (2021)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

Editorial: Personalized Medicine for Urological Cancers: Targeting Cancer Metabolism
por: Gunter, Jennifer H., et al.
Publicado: (2022)

Editorial: Cancer Metabolism: Molecular Targeting and Implications for Therapy
por: Ganapathy-Kanniappan, Shanmugasundaram
Publicado: (2017)

Editorial: Molecular Targets and Therapeutic Strategies in Gynecological Cancers
por: Lu, Ziwen, et al.
Publicado: (2022)

Editorial: Novel Molecular Targets and Treatments for Gastroesophageal Cancer
por: Lam, Alfred King-yin, et al.
Publicado: (2022)

Editorial: Advances in molecular targeted therapies of urologic cancers
por: Nitzsche, Bianca, et al.
Publicado: (2022)

Editorial: Targeting tumor vasculature to enhance cancer immunotherapy
por: Yang, Jieying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eaar6fc5hlb8rhjiuh1sbklnkg